[Neutrophil-endothelium interaction].
Tsuji
Shingo
S
Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine.
Kawano
Sunao
S
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001241:Aspirin / Q000009:adverse effects; D000068579:Celecoxib; D002448:Cell Adhesion / Q000187:drug effects; D015815:Cell Adhesion Molecules / Q000502:physiology; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D004730:Endothelium, Vascular / Q000166:cytology*; D005753:Gastric Mucosa / Q000098:blood supply; D006801:Humans; D007213:Indomethacin / Q000009:adverse effects; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D008565:Membrane Proteins; D008833:Microcirculation; D009504:Neutrophils / Q000502:physiology*; D010437:Peptic Ulcer / Q000139:chemically induced; D011451:Prostaglandin-Endoperoxide Synthases; D011720:Pyrazoles; D013449:Sulfonamides
D000894:Anti-Inflammatory Agents, Non-Steroidal; D015815:Cell Adhesion Molecules; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D011720:Pyrazoles; D013449:Sulfonamides; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D000068579:Celecoxib; D001241:Aspirin; D007213:Indomethacin